LEO Lymphoma Study Participants
The Lymphoma Epidemiology of Outcomes (LEO) Study is following up with existing participants and is engaged in targeted recruitment of new participants by invitation.
Eligibility and procedures
After providing informed consent, study participants must complete questionnaires, give a one-time blood sample, allow review of diagnostic biopsy material and permit study staff to review medical records.
Patients are eligible if they have been diagnosed with lymphoma within six months of enrollment and are actively being seen by a hematology provider at a participating center, including:
- Mayo Clinic
- Emory University or Grady Health System
- MD Anderson Cancer Center
- The University of Iowa
- University of Miami or Jackson Memorial Hospital
- University of Rochester Medical Center
- Washington University
- Weill Cornell Medical Center
Frequently asked questions
How will the LEO study benefit me?
While there is no direct benefit to you for participating in the LEO lymphoma study, data from the study help researchers gain a better understanding of what factors might lead to longer and better survival and survivorship in patients with non-Hodgkin's lymphoma.
The Mayo Clinic research team ultimately hopes to discover innovative methods to improve patient care and quality of life for people with lymphoma.
How long is the study?
The study tracks each participant for their entire survivorship experience because we're interested in both short-term and long-term outcomes. Data analysis is ongoing. The study was extended and is currently funded through March 2026.
How is my confidentiality protected?
Only the LEO lymphoma study personnel at Mayo Clinic know your identity, and each participating center can only view its own participants' information. Your identity isn't shared with any researcher outside of the study. Information learned about you through this study doesn't become part of your medical record.
I'm not getting treatment for my diagnosis. Can I still participate?
Yes. Participants must have been diagnosed within six months of enrollment to be eligible for participation in the LEO lymphoma study. Patients are eligible to participate regardless of their treatment status.
Is there a charge to participate?
No, participation in the study is free.
Will participating in the LEO study affect my cancer treatment?
No. Participation in the LEO study will not affect your cancer treatment or your medical care in any way.
For information about the Mayo Clinic LEO lymphoma study, contact Dr. Cerhan's team at 800-610-7093 (toll-free) or by email at email@example.com.
Visit the LEO Cohort website for more information.
You also can visit ClinicalTrials.gov to learn more about the Lymphoma Epidemiology of Outcomes cohort study.